Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients.
| Autor: | Jabbari H; Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran., Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, Zamini H, Shahzamani K, Merat S, Nassiri-Toosi M |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Archives of Iranian medicine [Arch Iran Med] 2010 Jul; Vol. 13 (4), pp. 306-12. |
| DOI: | 010134/AIM.0010 |
| Abstrakt: | Background: To evaluate the safety and effectiveness of locally produced pegylated interferon-alpha2a in treatment-naïve patients with chronic hepatitis C. Methods: All treatment-naïve patients diagnosed with chronic hepatitis C who referred to two university based outpatient clinics in Tehran from December 2007 to May 2008 were enrolled. Exclusion criteria included the presence of a debilitating disease, decompensated cirrhosis, or refusal to participate in the study. Patients were treated with 180 microg pegylated interferon-alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily for 24 or 48 weeks depending on genotype and weight. Viral and biochemical response and adverse drug reactions were recorded. Results: A total of 108 patients were enrolled; 63 with genotype 1 and 45 with genotypes 2 and 3. The mean age of the patients was 39 years (range: 19 - 65). Ninety-seven patients completed the study and 76 achieved sustained viral response. The sustained viral response among patients completing the study was 67% for genotype 1 and 95% for genotypes 2 and 3. Adverse events were well tolerated and none led to discontinuation of treatment, however dose adjustment was necessitated in 16 patients. The most common adverse events were fatigue (73.5%), poor appetite (66.2%), and feverishness (57.4%). The mean hemoglobin drop was 2.9 g/dL. Conclusion: Locally produced PEG-IFN in Iran is safe and effective in treatment-naïve chronic hepatitis C. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|